Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1978 May;32(2):253–258.

Inability to demonstrate lytic antibodies to autologous leukaemia cells in the sera from remission patients with acute myelogenous leukaemia treated with active specific immunotherapy.

B J Chapuis, R Powles, P Alexander
PMCID: PMC1541284  PMID: 276431

Abstract

The sera from seven patients with acute myelogenous leukaemia (AML) who had achieved a clinical remission and who were being maintained by weekly immunotherapy using irradiated allogeneic AML cells and BCG, were examined for the presence of antibodies which were lytic to autologous AML cells using either a complement- or cell-dependent assay. The AML cells had been stored at --179 degrees C and put into a short-term tissue culture prior to testing. At no time during the period of remission or relapse could cytotoxic activity to the autologous cells be detected, although all of the sera had lytic antibodies for some allogenic leukaemia cells. We concluded that the patients were capable of raising lytic antibodies to histocompatibility antigens but did not raise comparable lytic antibodies directed against a leukaemia-specific membrane antigen.

Full text

PDF
253

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chapuis B., Summersgill B. M., Cocks P., Howard P., Lawler S. D., Alexander P., Powles R. Test for cryopreservation efficiency of human acute myelogenous leukaemia cells relevant to clinical requirements. Cryobiology. 1977 Dec;14(6):637–648. doi: 10.1016/0011-2240(77)90018-9. [DOI] [PubMed] [Google Scholar]
  2. Gale D. G., MacLennan I. C. Cytotoxic antibody in acute myeloblastic leukaemia during immunotherapy: lack of tumour specificity. Br J Cancer. 1977 Mar;35(3):280–287. doi: 10.1038/bjc.1977.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gutterman J. U., Rossen R. D., Butler W. T., McCredie K. B., Bodey G. P., Sr, Freireich E. J., Hersh E. M. Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med. 1973 Jan 25;288(4):169–175. doi: 10.1056/NEJM197301252880401. [DOI] [PubMed] [Google Scholar]
  4. Klouda T. P., Lawler S. D., Powles R. L., Oliver R. T., Grant C. K. HL-A antibody response in patients with acute myelogenous leukaemia treated by immunotherapy. Transplantation. 1975 Mar;19(3):245–249. doi: 10.1097/00007890-197503000-00008. [DOI] [PubMed] [Google Scholar]
  5. Powles R. L., Balchin L. A., Smith C., Grant C. K. Some properties of cryopreserved acute leukemia cells. Cryobiology. 1973 Sep;10(4):282–289. doi: 10.1016/0011-2240(73)90044-8. [DOI] [PubMed] [Google Scholar]
  6. Powles R. L., Crowther D., Bateman C. J., Beard M. E., McElwain T. J., Russell J., Lister T. A., Whitehouse J. M., Wrigley P. F., Pike M. Immunotherapy for acute myelogenous leukaemia. Br J Cancer. 1973 Nov;28(5):365–376. doi: 10.1038/bjc.1973.162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Powles R. Immunotherapy for acute myelogenous leukaemia. Br J Cancer Suppl. 1973 Aug;1:262–265. [PMC free article] [PubMed] [Google Scholar]
  8. Trinchieri G., De Marchi M., Mayr W., Savi M., Ceppellini R. Lymphocyte antibody lymphocytolytic interaction (LALI) with special emphasis on HL-A. Transplant Proc. 1973 Dec;5(4):1631–1649. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES